Samjin Pharm (005500.KS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · South Korea · ISIN KR7005500004

Price
19,700.00 KRW
Market cap
249.36 bn KRW
P/E (2025)
10.32
P/S (2025)
0.81
Dividend yield
4.06 %
Net margin
7.82 %
Return on equity (ROE)
8.32 %
Return on assets (ROA)
5.14 %

Samjin Pharm financials

Fiscal year20242025
Revenue308.35 bn KRW309.13 bn KRW
Gross profit128.97 bn KRW125.08 bn KRW
Operating income31.64 bn KRW26.78 bn KRW
EBIT48.52 bn KRW27.05 bn KRW
Net income39.23 bn KRW24.17 bn KRW
Diluted EPS – continuing operations3,131.78 KRW1,909.49 KRW

Full history since 2013, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Samjin Pharm

Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also develops SA001, which is in Phase II clinical trial for the treatment for dry eye syndrome and Sjogren syndrome; SJP1804 medicine that is Phase I clinical trial to treat macular degeneration; and SJP1604, which is in Phase I clinical trial for cancer; SJP1901 and SJP1902 for cancer treatment; SJP 1801 to treat Alzheimer's and Parkinson's disease; SJP006, an anti-viral product; and SJP003 for treatment of diabetes. In addition, the company's preclinical product is SJP1602 for the treatment of cancer. Samjin Pharmaceuticals Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.